The Russian Direct Investment Fund (RDIF) and the Chinese biotechnology company Shenzhen Yuanxing Gene-tech have entered into an agreement on the production of more than 60 million doses of the anti-COVID19 Sputnik V vaccine, the fund said.
Produced volume will ensure the vaccination of more than 30 million people. The start of commercial production of the drug is scheduled for May 2021.
The Sputnik V vaccine has already been registered in 57 countries with a total population of over 1.5 billion people. The effectiveness of Sputnik V is 91.6%, as confirmed by the publication of data in The Lancet, one of the oldest and most respected medical journals in the world.
Sputnik V is one of the best coronavirus vaccines in the world, approved by over 50 countries. Partnership with Shenzhen Yuanxing Gene-tech for the production of Sputnik V in China will expand the opportunities for the production of additional volumes of the Russian drug, the demand for which is increasing around the world, “said Kirill Dmitriev, CEO of RDIF.
The vaccine is built on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for two vaccinations during vaccination, providing longer immunity than vaccines using the same delivery mechanism for both vaccinations.
